Featured Research

from universities, journals, and other organizations

New Drugs Could Be More Effective At Lowering Cholesterol

Date:
September 4, 2000
Source:
Howard Hughes Medical Institute
Summary:
Researchers have discovered two targets for a new generation of cholesterol-lowering drugs that should allow greater precision in managing cholesterol levels.

September 1, 2000 — Researchers have discovered two targets for a new generation of cholesterol-lowering drugs that should allow greater precision in managing cholesterol levels.

Related Articles


Howard Hughes Medical Institute (HHMI) investigator David J. Mangelsdorf and colleague Joyce J. Repa, an HHMI associate at the University of Texas Southwestern Medical Center, have switched off cholesterol uptake in mice using a drug that targets key cholesterol-governing receptors. Their experiments also reveal how the receptors, LXR and FXR, control genes that regulate the body’s cholesterol balance. Scientists from Tularik Inc., in South San Francisco and Ligand Pharmaceuticals in San Diego also collaborated on the research, which was published in the September 1, 2000, issue of the journal Science.

"Before this work, there were only hints that a protein-mediated mechanism for cholesterol uptake existed," said Mangelsdorf. "We believed that the process was not just a passive absorption through the cell membrane, but we needed proof to support this idea. Although the results from these studies in mice are promising, there's a long road ahead before these compounds can be considered for human clinical trials."

A key clue that cholesterol uptake is actively regulated emerged from studies showing that mice can selectively avoid absorbing ingested plant sterols, which have a chemical structure that is similar to cholesterol. A second clue came from the observation that strains of rats and mice differ in their ability to absorb cholesterol, suggesting that there is a genetic component to control of cholesterol metabolism.

Mangelsdorf said his team's current work began not as a search for the mechanism of cholesterol uptake, but as an effort to identify the hormone-like compounds—called ligands—that activate LXR and FXR. These two orphan nuclear receptors are proteins that have the ability to turn on genes in the nucleus, but their triggers remained unknown, hence the term "orphan."

"We were on a triple treasure hunt—to find possible ligands for these orphan receptors, to find their target genes and to characterize their biological roles," said Mangelsdorf.

In previous work, the scientists had shown that LXR and FXR were involved in disposing of excess cholesterol and in regulating bile acids. When the group knocked out the LXR genes in mice, they found that LXR controlled a key enzyme that produced bile acids from cholesterol. Bile acids are generated to shed excess cholesterol and to speed cholesterol absorption by making cholesterol more soluble.

"An important take-home lesson here is that because we could show that these nuclear receptors had very direct and specific actions on cholesterol balance, they are excellent targets for drugs to affect cholesterol levels," said Mangelsdorf. "Like many other such nuclear receptors, they are affected by drugs that can be taken orally and go right to the receptors."

The group's next step was to see whether turning on LXR or FXR could affect cholesterol uptake. While the scientists didn’t initially have a drug that turned on either LXR or FXR, they did know that the compound LG268 activates RXR, a protein that is required for both LXR and FXR activity. RXR latches on to both LXR and FXR, and helps them activate their target genes.

"Drugs like LG268 are especially promising because they are already being considered for clinical use for chemotherapy and diabetes," said Mangelsdorf. "But there had been no reason to test the drug’s effect on cholesterol metabolism because nobody knew about LXR and FXR. The development of drugs that specifically activate LXR or FXR may prove even more beneficial."

When Mangelsdorf and his colleagues treated mice with LG268, they found that the drug completely blocked the animals’ absorption of cholesterol. "This was an astounding and dramatic effect," said Mangelsdorf. "And it prompted us to try to understand both how the drug inhibited cholesterol absorption in the intestine and promoted excretion of excess cholesterol."

In extensive biochemical and genetic experiments on mice, the scientists showed that LG268 enhances FXR’s ability to repress a gene crucial for bile acid synthesis, thus reducing cholesterol absorption by interfering with its solubility. They also found that LG268 activated LXR’s ability to speed up production of ABC1, a reverse cholesterol transporter that moves excess cholesterol out of cells to the liver for excretion.

"We have discovered a potential therapeutic mechanism for regulating cholesterol absorption from the diet and resorption of circulating cholesterol. Also, we have identified a mechanism of cholesterol transport in the intestine and the potential regulated transporter," said Mangelsdorf.

Although LG268 does induce fatty acid synthesis—an unwanted side effect—Mangelsdorf believes that it may provide an excellent foundation for the rational design of LG268-like compounds that do not have side effects. This new generation of drugs to prevent cholesterol absorption could work in concert with current cholesterol-lowering drugs that inhibit internal cholesterol synthesis by the body. Such cholesterol-synthesis-inhibiting drugs, called statins, achieve a significant cholesterol-lowering effect, but they do not work for everyonesince the body continues to absorb cholesterol from the diet.

"Using both kinds of drugs could actually produce a net loss of cholesterol in the body," said Mangelsdorf. "By carefully monitoring drug dosages and cholesterol levels, you could essentially ‘dial-in’ exactly the level you wanted a person’s cholesterol level to be."

In future work, the scientists will aim to improve their understanding of the LXR- and FXR-regulatory machinery. They will also concentrate on figuring out how ABC1 works. In transporting cholesterol out of cells, ABC1 also eliminates cholesterol from immune cells called macrophages. These cells are the culprits that form artery-clogging fatty atherosclerotic plaques that can trigger heart attacks. Thus, using drugs to activate ABC1 may prevent plaque buildup, said Mangelsdorf.


Story Source:

The above story is based on materials provided by Howard Hughes Medical Institute. Note: Materials may be edited for content and length.


Cite This Page:

Howard Hughes Medical Institute. "New Drugs Could Be More Effective At Lowering Cholesterol." ScienceDaily. ScienceDaily, 4 September 2000. <www.sciencedaily.com/releases/2000/09/000904092949.htm>.
Howard Hughes Medical Institute. (2000, September 4). New Drugs Could Be More Effective At Lowering Cholesterol. ScienceDaily. Retrieved December 22, 2014 from www.sciencedaily.com/releases/2000/09/000904092949.htm
Howard Hughes Medical Institute. "New Drugs Could Be More Effective At Lowering Cholesterol." ScienceDaily. www.sciencedaily.com/releases/2000/09/000904092949.htm (accessed December 22, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, December 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Christmas Kissing Good for Health

Christmas Kissing Good for Health

Reuters - Innovations Video Online (Dec. 22, 2014) Scientists in Amsterdam say couples transfer tens of millions of microbes when they kiss, encouraging healthy exposure to bacteria. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Brain-Dwelling Tapeworm Reveals Genetic Secrets

Brain-Dwelling Tapeworm Reveals Genetic Secrets

Reuters - Innovations Video Online (Dec. 22, 2014) Cambridge scientists have unravelled the genetic code of a rare tapeworm that lived inside a patient's brain for at least four year. Researchers hope it will present new opportunities to diagnose and treat this invasive parasite. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Touch-Free Smart Phone Empowers Mobility-Impaired

Touch-Free Smart Phone Empowers Mobility-Impaired

Reuters - Innovations Video Online (Dec. 21, 2014) A touch-free phone developed in Israel enables the mobility-impaired to operate smart phones with just a movement of the head. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Earthworms Provide Cancer-Fighting Bacteria

Earthworms Provide Cancer-Fighting Bacteria

Reuters - Innovations Video Online (Dec. 21, 2014) Polish scientists isolate bacteria from earthworm intestines which they say may be used in antibiotics and cancer treatments. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins